The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis
Abstract
BACKGROUND An Investigator Global Assessment (IGA) is recommended by health agencies for drug registration in atopic dermatitis (AD). Current IGA scales lack standardization. OBJECTIVES To develop an IGA scale, training module, and clinical certification exam for use in AD trials, and establish content validity and assess reliability. METHODS Expert dermatologists participated in the development of the validated IGA for AD (vIGA-AD™). Reliability (inter-rater and intra-rater) was assessed by 2 web-based surveys. Clinical certification for investigators consisted of a training module and exam. RESULTS Expert consensus was achieved around a 5-point IGA scale including morphological descriptions, and content validity was established. Survey 1 showed strong inter-rater reliability (Kendall's coefficient of concordance W [Kendall's W] = 0.809, intra-class correlation [ICC] = 0.817) and excellent agreement (weighted Kappa = 0.857). Survey 2, completed 5 months after training of dermatologists, showed improvements in scale reliability (Kendall's W = 0.819, ICC = 0.852, weighted Kappa = 0.889). In this study 627 investigators completed vIGA-AD training and certification. LIMITATIONS Ratings were assessed on photographs. CONCLUSION A validated IGA scale and training module were developed with the intent of harmonizing assessment of disease severity in AD trials. Strong reliability and excellent agreement between assessments were observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 9×
“Reliability testing of the vIGA-AD scale and survey content Web-based surveys were developed to assess the reliability of the vIGA-AD.”
MethodInfluentialSelf-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
What are the best outcome measurements for atopic eczema? A systematic review
Schmitt, J., Langan, S., & Williams, H. C. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.08.011 · Cited by 388 · cited 1×
“Dr Beck reports honoraria for advisory board or nsulting services from AbbVie, Allakos, Arena Pharmaceuticals, AstraZe and Company, LEO Pharm Sanofi, UCB, and Vimalan investigator from AbbVie, and owns stock in Pfize honoraria for advisory bo AbbVie, Almirall, Anapty Daiichi-Sankyo, Dermavan mark Pharma, Incyte, Kym M…”
BackgroundTherapeutic pipeline for atopic dermatitis: End of the drought?
Paller, A. S., Kabashima, K., & Bieber, T. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.006 · Cited by 192
Self-citation
Cited by
Guttman-Yassky, E., Teixeira, H. D., Simpson, E. L., Papp, K. A., Pangan, A. L., Blauvelt, A., Thaçi, D., Chu, C.-Y., Hong, H. C.-H., Katoh, N., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00588-2 · Cited by 583
Self-citationReich, K., Teixeira, H. D., de Bruin-Weller, M., Bieber, T., Soong, W., Kabashima, K., Werfel, T., Zeng, J., Huang, X., Hu, X., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00589-4 · Cited by 402
Self-citationJAK inhibitors in the treatment of atopic dermatitis
Chovatiya, R., & Paller, A. S. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.08.009 · Cited by 398
Self-citationChu, D. K., Schneider, L., Asiniwasis, R. N., Boguniewicz, M., De Benedetto, A., Ellison, K., Frazier, W. T., Greenhawt, M., Huynh, J., Kim, E., et al. (2024) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2023.11.009 · Cited by 380
Self-citationNakatsuji, T., Hata, T. R., Tong, Y., Cheng, J. Y., Shafiq, F., Butcher, A. M., Salem, S. S., Brinton, S. L., Rudman Spergel, A. K., Johnson, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01256-2 · Cited by 333
Metadata
- Authors
- Simpson, E., Bissonnette, R., Eichenfield, L. F., Guttman-Yassky, E., King, B., Silverberg, J. I., Beck, L. A., Bieber, T., Reich, K., Kabashima, K., Seyger, M., Siegfried, E., Stingl, G., Feldman, S. R., Menter, A., van de Kerkhof, P., Yosipovitch, G., Paul, C., Martel, P., Dubost-Brama, A., Armstrong, J., Chavda, R., Frey, S., Joubert, Y., Milutinovic, M., Parneix, A., Teixeira, H. D., Lin, C.-Y., Sun, L., Klekotka, P., Nickoloff, B., Dutronc, Y., Mallbris, L., Janes, J. M., DeLozier, A. M., Nunes, F. P., & Paller, A. S.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 83
- Issue
- 3
- Pages
- 839-846
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W3017839166
- Cited by
- 183
- References
- 4
- FWCI
- 13.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.